The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010–2019

References

• Mokaddas EM, Rotimi VO, Albert MJ. Implications of Streptococcus pneumoniae penicillin resistance and serotype distribution in Kuwait for disease treatment and prevention. Clin Vaccine Immunol. 2008;15:203–07. doi:10.1128/CVI.00277-07.
   PubMed Web of Science ®Google Scholar
• LeeLH, Gu-X-X, Nahm MH. Towards new broader spectrum pneumococcal vaccines: the future of pneumococcal disease prevention. Vaccines. 2014;2:112–28. doi:10.3390/vaccines2010112.
   PubMedGoogle Scholar
• Mokaddas E, Albert MJ. Serotype distribution and penicillin non-susceptibility of Streptococcus pneumoniae causing invasive diseases in Kuwait: a 10-year study of impact of pneumococcal conjugate vaccines. Expert Rev Vaccines. 2016;15:1337–45. doi:10.1080/14760584.2016.1198698.
   PubMed Web of Science ®Google Scholar
• Mokaddas EM, Shibl AM, Elgouhary A, Elsobky M. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia. Vaccine. 2018;36:6442–48. doi:10.1016/j.vaccine.2018.07.067.
   PubMed Web of Science ®Google Scholar
• Sorensen UB. Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol. 1993;31:2097–100. doi:10.1128/jcm.31.8.2097-2100.1993.
   PubMed Web of Science ®Google Scholar
• Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011. Emerg Infect Dis. 2013;19:1074–83. doi:10.3201/eid1907.121830.
   PubMed Web of Science ®Google Scholar
• Linley E, Bell A, Gritzfeld JF, Borrow R. Should pneumococcal serotype 3 be included in serotype-specific immunoassay?Vaccines (Basel). 2019;7:4. doi:10.3390/vaccines7010004.
   PubMed Web of Science ®Google Scholar
• Singleton R, Wenger J, Kleja J, Bulkow LR, Thompson A, Sarkozy D, Emilio E, Gruber WC, Scott DA. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Ped Infect Dis J. 2013;32:257–63. doi:10.1097/INF.0b013e3182748ada.
   PubMed Web of Science ®Google Scholar
• Demczuk HB, Martin I, Griffith A, Lefebvre B, McGeer A, Shane A, Zhanel GG, Tyrrell GJ, Gilmour MW. Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010. Can J Microbiol. 2012;58:1008–17. doi:10.1139/w2012-073.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32:3452–59.
   PubMed Web of Science ®Google Scholar
• Nurhonen M, Cheng AC, Auranen K. Pneumococcal transmission and disease in silico: a microsimulation model of the indirect effects of vaccination. PLoS One. 2013;8:e56079. doi:10.1371/journal.pone.0056079.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Impacts of the 13-valent pneumococcal conjugate vaccine in children. J Immunol Res. 2015;article ID 591580
   Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a post licensure indirect cohort study. Lancet Infect Dis. 2014;14:839–46. doi:10.1016/S1473-3099(14)70822-9.
   PubMed Web of Science ®Google Scholar
• Kandasamy R, Voysey M, Collins S, Berbers G, Robinson H, Noel I, Hughes H, Ndimah S, Gould K, Fry N, et al. Persistent circulation of vaccine serotypes and serotype replacement after 5 Years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom. J Infect Dis. 2020;221:1361–70.
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59:1066–73. doi:10.1093/cid/ciu524.
   PubMed Web of Science ®Google Scholar
• Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjostrom K, Morfeldt E, Naucler P, Blennow M, Ortqvist A, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Resp J. 2016;47:1208–18. doi:10.1183/13993003.01451-2015.
   PubMed Web of Science ®Google Scholar
• Siber GR, Chang I, Baker S, Fernsten P, O’Brien KL, Santosham M, Klugman KP, Madhi SA, Paradiso P, Kohberger R. Estimating the protective concentration of anti-pneumococcal capsularpolysaccharide antibodies.Vaccine.2007;25:3816–26. doi:10.1016/j.vaccine.2007.01.119.
   PubMed Web of Science ®Google Scholar
• van Westen E, Knol MJ, Wijmenga-Monsuur AJ, Tcherniaeva I, Schouls LM, Sanders EAM, Van Els CACM, Berbers GAM, Rots NY. Serotype-specific IgG antibody waning after pneumococcal conjugate primary series vaccinations with either the 10-valent or the 13-valent vaccine. Vaccines. 2018;6:82. doi:10.3390/vaccines6040082.
   Web of Science ®Google Scholar
• Fjeldhoj S, Fuglsang E, Sorensen CA, Frokiaer H, Krogfelt KA, Laursen RP, Slotved H-C. Factors influencing PCV13 specific antibody response in Danish children starting in day care. Sci Rep. 2020;10:6179. doi:10.1038/s41598-020-63080-x.
   PubMed Web of Science ®Google Scholar
• Lapidot R, Shea KM, Yildirim I, Cabral HJ, Pelton SI. Characteristics of serotype 3 invasive pneumococcal disease before and after universal childhood immunization with PCV13 in Massachusetts. Pathogens. 2020;9:396. doi:10.3390/pathogens9050396.
   PubMed Web of Science ®Google Scholar
• Horacio AN, Silva-Costa C, Lopez JP, Ramirez M, Melo-Cristino J. Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol. 2016;7:1616. doi:10.3389/fmicb.2016.01616.
   PubMed Web of Science ®Google Scholar
• Luck JN, Tettelin H, Orihuela CJ. Sugar-coated killer: serotype 3 pneumococcal disease. Front Cell Infect Microbiol. 2020;10:613287. doi:10.3389/fcimb.2020.613287.
   PubMed Web of Science ®Google Scholar
• McAllister LJ, Ogunniyi AD, Stroeher UH, Leach AJ, Paton JC. Contribution of serotype and genetic background to virulence of serotype 3 and serogroup 11 pneumococcal isolates. Infect Immun. 2011;79:4839–49. doi:10.1128/IAI.05663-11.
   PubMed Web of Science ®Google Scholar
• Moraga-Llop F, Garcia-Garcia -J-J, Diaz-Conradi A, Ciruela P, Martinez-Osorio J, Gonzalez-Peris S, Hernanadez S, de Sevilla MF, Uriona S, Izquierdo C, et al. Vaccine failures in patients properly vaccinated with 13-valent pneumococcal conjugate vaccine in Catalonia, a region with low vaccination coverage.Ped Infect Dis J. 2016;35:460–63. doi:10.1097/INF.0000000000001041.
   PubMed Web of Science ®Google Scholar
• Diawara I, Zerouali K, Elmdaghri N, Abid A. A case report of parapneumonic pleural effusion caused by Streptococcus pneumoniae serotype 19A in a child immunized with 13-valent conjugate pneumococcal vaccine. BMC Pediatr. 2017;17:114. doi:10.1186/s12887-017-0872-2.
   PubMed Web of Science ®Google Scholar
• Silva-Costa C, Gomes-Silva J, Teodoro I, Ramirez M, Melo-Cristino J. Invasive pneumococcal disease in adults in Portugal: the importance of serotypes 8 and 3. Microorganisms. 2021;9:1016. doi:10.3390/microorganisms9051016.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18:441–51. doi:10.1016/S1473-3099(18)30052-5.
   PubMed Web of Science ®Google Scholar
• Gonsalez-Diaz A, Camara J, Ercibengoa M, Marimon JM, Yuste J, Ardanuy C. Emerging non-13 valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late PCV13 period in Spain. Clin Microbiol Infect. 2020;26:753–59. doi:10.1016/j.cmi.2019.10.034.
   PubMed Web of Science ®Google Scholar
• Lochen A, Croucher NJ, Anderson RM. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep. 2020;10:18977. doi:10.1038/s41598-020-75691-5.
   PubMed Web of Science ®Google Scholar
• Mohale T, Wolter N, Allam M, Ndlangisa K, Crowther-Gibson P, Du Plessis M, von Gottberg A. Genomic analysis of nontypeable pneumococci causing invasive pneumococcal disease in South Africa, 2003–2013. BMC Genom. 2016;17:470. doi:10.1186/s12864-016-2808-x.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Hoover PA, Vesikari T, Peltier C, Hurley DC, McFetridge RD, Dallas M, Hartzel J, Marchese RD, Coller B-AG, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018;36:6883–91. doi:10.1016/j.vaccine.2018.02.113.
   PubMed Web of Science ®Google Scholar
• Thompson A, Lamberth E, Severs J, Scully I, Tarabar S, Ginis J, Jansen KU, Gruber WC, Scott DA, Watson W. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2019;37:6201–07. doi:10.1016/j.vaccine.2019.08.048.
   PubMed Web of Science ®Google Scholar